Breaking Down Shanghai Shyndec Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Peeling back the numbers behind Shanghai Shyndec Pharmaceutical Co., Ltd. reveals a company in transition: sales for the nine months to September 30, 2025 fell to CNY 6.92 billion (TTM revenue as of June 2025: CNY 9.85 billion, down from CNY 10.42 billion), while net income for the same nine-month period slid to CNY 801.17 million and TTM net income stands at CNY 1.11 billion with a profit margin of 10.69%; investors are valuing the firm at a market capitalization of CNY 13.91 billion with a P/E of 13.05, P/S of 1.50 and P/B of 1.07, even as revenue per share TTM is CNY 7.35 and EPS TTM is CNY 0.83-contrasted by liquidity metrics like a robust current ratio of 3.32 and operating cash flow TTM of CNY 1.85 billion but a negative levered free cash flow of CNY -98.79 million; notable risks include a 19.45% decline in revenue over the trailing year and a surge in raw material costs of 102.84%, while growth levers persist in a diversified product portfolio, nearly 12,000-employee footprint across 23 subsidiaries and ongoing manufacturing and environmental upgrades that could reshape future performance.

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Revenue Analysis

Shanghai Shyndec Pharmaceutical Co., Ltd. shows clear signs of top-line contraction over the latest reporting windows, with both period and trailing figures declining while valuation metrics and productivity measures provide additional context for investors.

• Nine months ended Sep 30, 2025: Sales CNY 6.92 billion, down from CNY 8.59 billion in the same period prior year.
• TTM revenue as of Jun 2025: CNY 9.85 billion, down from CNY 10.42 billion in the previous TTM period.
• Revenue per share (TTM as of Jun 2025): CNY 7.35, versus CNY 7.77 in the prior TTM - indicating per-share top-line pressure.
• Price-to-Sales (P/S) ratio: 1.50 - investors are paying CNY 1.50 for every CNY 1 of revenue.
• Revenue per employee: ~CNY 807,580, based on 11,472 employees - a proxy for operational productivity.
• Market capitalization: CNY 13.91 billion - current market valuation relative to revenue and growth trajectory.

• Implication: declining revenue and revenue per share suggest pressure on growth drivers (pricing, volumes, product mix or distribution) that investors should probe further.
• Valuation context: P/S of 1.50 positions the stock between bargain and neutral relative to growth - examine profitability and margins to assess fairness of this multiple.
• Productivity lens: revenue per employee (~CNY 0.81M) can be compared with peers to judge operational efficiency and labor intensity of the business model.

For additional investor-focused details and shareholder composition context, see: Exploring Shanghai Shyndec Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Profitability Metrics

• Net income (9M ending Sep 30, 2025): CNY 801.17 million (down from CNY 954.53 million in 9M prior year).
• Trailing twelve months (TTM) net income as of Jun 2025: CNY 1.11 billion; profit margin (TTM): 10.69%.
• Operating margin (TTM): 18.72% - portion of revenue remaining after operating expenses.
• Return on assets (ROA, TTM): 4.84% - efficiency in using assets to generate profit.
• Return on equity (ROE, TTM): 8.72% - return on shareholders' equity.
• Earnings per share (EPS, TTM, diluted): CNY 0.83.

• Margin structure: operating margin (18.72%) well above net/profit margin (10.69%), indicating notable non-operating costs, taxes, interest or one-offs reducing bottom-line conversion.
• Returns: ROE (8.72%) vs ROA (4.84%) suggests moderate leverage amplifying equity returns but overall asset efficiency is modest.
• EPS context: CNY 0.83 (diluted) indicates earnings available per share on a TTM basis; compare to share price for P/E perspective.

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Debt vs. Equity Structure

• Total debt to equity ratio: 0.70 - a moderate leverage level that implies the company uses debt conservatively relative to shareholder equity, reducing financial distress risk while allowing for tax-efficient financing.
• Current ratio: 3.32 - strong short-term liquidity indicating the company can cover current liabilities more than three times with current assets, lowering near-term default risk.
• Book value per share: CNY 10.12 - the net asset value attributable to each share, useful as a floor valuation reference for equity investors.
• Enterprise value / Revenue: 1.10 - the market's valuation of the company is roughly 1.1x annual revenue, signaling a moderate revenue multiple compared with peers in pharma/manufacturing.
• Enterprise value / EBITDA: 5.09 - suggesting an EV-based earnings multiple in the mid-single digits, generally indicative of attractive valuation relative to stable earnings.
• Market capitalization: CNY 13.91 billion - the total equity market value, important for size-relative risk and liquidity considerations.

• Leverage profile (0.70) combined with a high current ratio (3.32) implies financial flexibility - the firm can service debt while funding operations or R&D without immediate refinancing pressure.
• EV/EBITDA of 5.09 points to a valuation that could be favorable relative to growth prospects or industry comparables, but should be assessed alongside profitability trends and margin sustainability.
• Book value per share (CNY 10.12) and market cap (CNY 13.91 billion) provide anchors for equity valuation analysis - compare market price per share to book value and peers to gauge upside or downside.

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Liquidity and Solvency

Key liquidity and solvency metrics for Shanghai Shyndec Pharmaceutical highlight robust short-term coverage but mixed cash-flow dynamics when debt servicing is considered. Below are the principal figures investors should weigh.

• Current ratio: 3.32 - indicates strong short-term liquidity and ability to meet current obligations.
• Quick ratio: Not specified in available data.
• Cash ratio: Not specified in available data.
• Operating cash flow (TTM): CNY 1.85 billion - cash generated from core operations over the trailing twelve months.
• Levered free cash flow (TTM): CNY -98.79 million - negative after accounting for interest and debt-related cash flows.
• Market capitalization: CNY 13.91 billion - current market valuation.

For broader context on company background and strategy, see: Shanghai Shyndec Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Valuation Analysis

Key valuation metrics for Shanghai Shyndec Pharmaceutical Co., Ltd. provide a snapshot of how the market currently prices the company relative to earnings, sales, book value and cash-generation capability. Below are the principal ratios and concise interpretations to help investors gauge relative cheapness, growth expectations and balance-sheet backing.

• Trailing twelve months (TTM) P/E: 13.05 - implies a moderate valuation relative to historical earnings.
• Forward P/E: 10.51 - signals anticipated earnings growth that lowers the price paid per unit of forecast earnings.
• Price-to-Sales (P/S): 1.50 - investors are paying 1.50x annual revenue.
• Price-to-Book (P/B): 1.07 - market value is close to book value, indicating limited intangible premium priced in.
• Enterprise Value / Revenue (EV/Rev): 1.10 - overall valuation is approximately 1.10x annual revenue on an enterprise basis.
• Enterprise Value / EBITDA (EV/EBITDA): 5.09 - suggests relatively low enterprise valuation versus operating cash-profit, often seen as attractive if sustainable.

Key considerations for investors when interpreting these metrics:

• Lower forward P/E versus TTM P/E can reflect genuine expected earnings growth or short-term boosts to consensus estimates.
• A P/B near 1.0 suggests limited market premium for intangibles - check asset quality, R&D capitalization and impairment risk.
• EV/EBITDA at ~5x is typically supportive of acquisition interest or signals undervaluation if EBITDA is sustainable; confirm margin stability and recurring revenue sources.
• Compare P/S and EV/Rev with domestic peers to assess whether the 1.50 / 1.10 levels are sector-competitive or company-specific.

For broader context on ownership, trading activity and investor interest that may influence valuation dynamics, see: Exploring Shanghai Shyndec Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Risk Factors

Investors assessing Shanghai Shyndec Pharmaceutical should weigh several material risks that have emerged from the company's most recent operating and financial performance. Below are the principal risk drivers supported by the latest reported figures (periods ending September 30, 2025 unless otherwise noted).

• Revenue contraction: Trailing twelve months (TTM) revenue declined 19.45%, signaling reduced top-line momentum and potential demand or pricing pressure.
• Profitability deterioration: Net income fell 15.99% year-to-date (nine months), compressing margins and reducing retained earnings available for reinvestment or debt service.
• Liquidity constraints: Operating cash flow reached a low of CNY 770.77 million, amplifying short-term liquidity risk and reliance on external financing if cash generation does not recover.
• Input-cost inflation: Raw material costs surged 102.84% YoY, directly pressuring gross margins and increasing the risk that higher costs cannot be fully passed through to customers.
• Negative post-debt cash flow: Levered free cash flow (TTM) is negative at CNY -98.79 million, indicating net cash outflows after servicing debt - a red flag for solvency under stress scenarios.
• Market underperformance: The company's stock is down 12.81% year-to-date versus a 19.83% gain for the Shanghai Composite, reflecting investor concern and potentially higher cost of equity.

Key scenario and sensitivity considerations for investors:

• Margin sensitivity: With raw material costs up >100% YoY, a 1-3 percentage-point inability to pass costs through could materially erode operating margin and drive further net losses.
• Cash runway: Negative levered FCF combined with low operating cash flow suggests limited internal funding for capex or expansion without refinancing - examine debt maturities and covenant headroom.
• Market sentiment and liquidity: Persistent underperformance vs. the Shanghai Composite may constrain equity-raising alternatives and depress valuation multiples in the near term.
• Operational risk: Continued revenue declines magnify execution risk on product launches, pricing strategy, and market share retention in a competitive pharmaceutical landscape.

For more on the company's strategic framing and stated priorities, see: Mission Statement, Vision, & Core Values (2026) of Shanghai Shyndec Pharmaceutical Co., Ltd.

Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SS) - Growth Opportunities

• Corporate footprint: 23 wholly-owned or partially-owned subsidiaries (13 second-tier; 10 third-/fourth-tier) supporting geographic and product diversification.
• Workforce scale: approximately 12,000 employees, enabling production scale, R&D throughput and distribution coverage.
• Product breadth: core offerings include 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, multiple antibiotics and other finished dosage forms and APIs.
• Integrated supply chain: distribution system spans APIs to finished dosage forms, including anesthetic and psychotropic substance streams-supporting margin capture across the value chain.
• Operational sustainability: recognized as a waste-free factory and recently completed low-nitrogen boiler upgrades, dust emission controls and wastewater treatment improvements.
• Market valuation: market capitalization of CNY 13.91 billion, reflecting investor capitalization of current and expected future cash flows.

• Scale-driven margin improvement: leveraging 12,000-employee platform and multi-tier subsidiaries to increase manufacturing throughput for high-margin APIs (6-APA, potassium clavulanate) and finished forms.
• Product mix optimization: expand diclofenac sodium extended release and differentiated antibiotic formulations into higher-value branded or hospital channels.
• Regulatory & distribution advantage: established anesthetic/psychotropic distribution pathways can accelerate market access for adjacent specialty products with higher reimbursement potential.
• Sustainability premium: waste-free certification and environmental upgrades reduce compliance risk and can unlock preferred procurement or financing terms tied to ESG performance.
• M&A and JV runway: 23-subsidiary structure and multi-tier footprint facilitate bolt-on acquisitions or joint ventures to fill therapeutic gaps or expand geographic reach without overhauling core operations.
• Operational efficiency drives: completion of boiler, dust and wastewater projects lowers variable costs and mitigates bottlenecks-translating into improved unit economics and capacity to meet rising demand.